Pfizer has reported higher third-quarter profit as aggressive cost-cutting offset a negative foreign exchange impact and declining sales of drugs, including those facing competition from cheaper generics.

The drug-maker, which got much bigger last week with its $67.3 billion (¤45 billion) acquisition of Wyeth, posted a net profit of $2.88 billion, up on $2.28 billion a year ago. – (Reuters)